Boehringer links up with A*STAR to develop antibodies

Germany’s Boehringer Ingelheim and Singapore’s Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Family-owned pharma major Boehringer aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.

“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive Wood, senior corporate vice president and global head of discovery research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”